TL;DR: This week: TRIUMPH-2 reached The Lancet (29-30 Sept), the 7th Circuit retatrutide appeal stayed undecided, and no FDA peptide rule appeared.
Peptide Research Week in Review: 29 September-3 October 2026
What Happened in Peptide Research This Week (29 Sep-3 Oct 2026)?
The week's one scheduled data event was the European Association for the Study of Diabetes (EASD) annual meeting in Milan, where Eli Lilly presented the full TRIUMPH-2 Phase 3 results for retatrutide, with a simultaneous publication in The Lancet, reported on 29–30 September.[1][2] The two other threads we track were notable for what did not happen: the US Seventh Circuit has not ruled on Lilly's retatrutide biologic-classification appeal, argued on 24 September,[3] and, per reporting, no proposed FDA rule has yet moved any peptide from July's advisory-committee vote onto the 503A Bulks List.[4]
Everything below is third-party reporting on pharmaceutical, legal and regulatory developments. It is not a description of, or endorsement of, any use of research reagents outside the laboratory. For last week's digest, see Peptide Research Week in Review: 22-28 September 2026.
What Did the TRIUMPH-2 Lancet Paper Add?
Design: Double-blind, parallel-group, randomised, placebo-controlled; retatrutide 4, 9 and 12 mg once weekly versus placebo (NCT05929079).[5]
Reported adverse events (4 / 9 / 12 mg versus placebo): diarrhoea 27.4% / 33.5% / 33.6% versus 13.2%; nausea 13.7% / 20.8% / 28.0% versus 8.0%; dysesthesia 4.5% / 5.6% / 7.3% versus 0.7%. Discontinuation due to adverse events was 3.8% / 11.6% / 7.7% versus 4.9%.[2]
Source: The Lancet · figures as reported by Healio, 30 September 2026
The headline efficacy numbers match what Lilly disclosed in its 23 July topline release, so the publication is best read as the peer-reviewed record rather than a new result. We covered the topline in our TRIUMPH-2 and TRIUMPH-3 guide and the pre-conference outlook in our EASD preview; the paper's tolerability tables are examined in our safety and tolerability guide.
One detail worth flagging for researchers: the dysesthesia rate at 12 mg (7.3%) is well below the 20.9% reported in TRIUMPH-4 at ADA 2026, though the trials enrolled different populations and were not designed for direct comparison. Our dysesthesia guide sets out the TRIUMPH-4 data. As ever, a dose-by-adverse-event table in a licensed-pharma trial frames laboratory questions; it does not validate any use of a research reagent outside the lab.
Where Does the Seventh Circuit Retatrutide Appeal Stand?
Unchanged since the hearing. The Seventh Circuit heard oral arguments in Eli Lilly and Company v. Kennedy on 24 September 2026, and the case is under advisement with no ruling issued as of 3 October.[3] Lilly is asking the appellate court to go further than the district court and hold that retatrutide is a biologic as a matter of law, rather than merely finding the FDA's analysis inadequate. The practical stake is regulatory: under Section 503A, biologics cannot be compounded, so the classification determines whether a compounding pathway could ever exist for the molecule.
Appellate decisions of this kind commonly take months, so a quiet week is the expected outcome rather than a signal. Our guides to what happens after the hearing and the DOJ's Franco v. Chobani letter cover the procedural detail.
Has FDA Acted on the July Peptide Advisory Vote?
Not according to current reporting. FDA's Pharmacy Compounding Advisory Committee (PCAC) met on 23–24 July 2026 and narrowly recommended six of seven peptides under review — BPC-157, KPV, TB-500, MOTS-c, Semax and epitalon — for the 503A Bulks List, including an 8-6 vote with one abstention on BPC-157.[4] The vote is non-binding. Legal analyses published since note that, as of mid-September, none of the six appeared on the list and no proposed rule adding them had been published, so the status quo for US compounding is unchanged.[6]
FDA reviewers had cited short, underpowered studies and limited human data for BPC-157 at the meeting.[4] For the committee's composition and the arguments on each side, see our PCAC vote outcome guide and the industry-ties analysis. Nothing in a US advisory vote changes UK law or the research-use status of any compound; see are research peptides legal in the UK.
What Should Researchers Watch Next?
Three items are worth tracking. First, any Seventh Circuit opinion in the retatrutide case, which could land without notice. Second, publication of the TRIUMPH-2 full-text supplementary tables, where subgroup and safety detail beyond the abstract is typically found. Third, any Federal Register notice on the 503A Bulks List, which would be the first formal step after the July vote. Lilly's stated plan remains a Biologics License Application for retatrutide in Q1 2027; our filing-timeline guide explains the manufacturing-data context.
Does This Week's News Change UK Research-Reagent Supply?
No. Retatrutide remains an investigational compound with no marketing authorisation from the FDA, MHRA or any regulator, and none of this week's developments alters the position for in vitro research use in the UK. Velox Peptides supplies retatrutide strictly as an HPLC-verified research reagent, with no health or therapeutic claims. Researchers should verify any reagent against its certificate of analysis; see how to read a CoA.
This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- “Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.” The Lancet, September 2026. thelancet.com
- Healio. “Retatrutide confers ‘substantial’ weight loss for adults with obesity, type 2 diabetes.” 30 September 2026. healio.com
- Velox Peptides. “Retatrutide's Seventh Circuit Hearing Was Held — What Happens Next.” veloxpeps.com
- AJMC. “FDA Panel Backs 6 Peptides for Compounding.” July 2026. ajmc.com
- ClinicalTrials.gov. NCT05929079
- Frier Levitt. “FDA PCAC Peptide Vote: What the 503A Recommendations Mean.” frierlevitt.com
Frequently Asked Questions
What happened in peptide research between 29 September and 3 October 2026?
Three things stood out: Lilly's TRIUMPH-2 retatrutide Phase 3 trial was presented at EASD in Milan and published in The Lancet (reported 29-30 September); the US Seventh Circuit had not ruled on Lilly's retatrutide biologic-classification appeal argued on 24 September; and, per reporting, no proposed FDA rule had yet added any peptide from July's advisory vote to the 503A Bulks List.
Was there a new retatrutide trial readout this week?
The TRIUMPH-2 full paper and EASD presentation were the week's retatrutide data event. The headline figures matched Lilly's 23 July 2026 topline release; the new detail was in the peer-reviewed safety and tolerability tables.
Has the Seventh Circuit ruled on retatrutide?
Not as of 3 October 2026. The panel heard arguments on 24 September and the case is under advisement; appellate decisions can take months.
Can BPC-157 be compounded in the US after the July FDA advisory vote?
Per reporting, not yet. The advisory committee's July vote was non-binding, and as of mid-September the 503A Bulks List did not include BPC-157, TB-500, KPV, MOTS-c, Semax or epitalon, with no proposed rule published.
Is retatrutide legal to buy in the UK for research?
Yes, for in vitro research purposes only. It is not a licensed medicine and is not approved for human use. Velox Peptides supplies it strictly as a research reagent under its Research Use Policy.